EUVIMEDEUVIMED entdecken
Open Access

Philadelphia-Like Genetic Rearrangements in Adults With B-Cell ALL: Refractoriness to Chemotherapy and Response to Tyrosine Kinase Inhibitor in ABL Class Rearrangements

Jayastu Senapati iD, Elias Jabbour iD, Marina Konopleva iD, Nicholas J Short iD, Guilin Tang iD, Naval Daver iD, Partow Kebriaei, Tapan Kadia iD, Naveen Pemmaraju iD, Koichi Takahashi iD, Courtney DiNardo iD, Koji Sasaki iD und 9 weitere

JCO Precision Oncology · 2023

DOI: 10.1200/po.22.00707 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JCO Precision Oncology, 2023. Verfasst von Jayastu Senapati und 20 weiteren Autor:innen. Beteiligte Einrichtung: Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX. Hauptthemen laut MEDLINE: Gene Rearrangement, Tyrosine Kinase Inhibitors. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE Philadelphia-like (Ph-like) B-cell ALL is a high-risk subtype of B-cell ALL that shares a gene expression profile with Ph-positive ALL, but without a BCR::ABL1 fusion. A subgroup of these patients have fusions or rearrangements involving genes such as ABL1, ABL2, PDGFRβ, JAK2, and EPOR, some of which are potentially sensitive to tyrosine kinase inhibitors (TKIs). Prompt identification of these genetic aberrations are important for prognostication and treatment decisions. PATIENTS AND METHODS We performed a retrospective review of patients with B-cell ALL treated at MD Anderson Cancer Center to identify recurrent genetic fusions commonly seen in Ph-like ALL and focus on patients treated with TKI. RESULTS We identified 23 patients with recurrent genetic fusions commonly seen in Ph-like ALL; 14 had ABL class fusions (eight ABL1, one ABL2, and five PDGFRβ) and nine had JAK2 class fusions (five JAK2 and four EPOR). Notably, several of these fusions were cryptic by conventional cytogenetics and fluorescent in situ hybridization (FISH) assays and identified only by multiplex fusion assay. Thirteen of these 23 patients received a TKI as part of their treatment; this included ABL1 fusion (n = 8), PDGFRβ fusion (n = 4), and EPOR fusion (n = 1). All four patients with ABL1 fusions who received TKI with induction chemotherapy are alive in first remission. CONCLUSION Understanding the genomics of B-cell ALL is important for disease prognostication and for precise treatment planning. Besides conventional cytogenetics and directed FISH testing, multiplex fusion assays can help identify recurrent chromosomal translocations that are seen in patients with Ph-like ALL. Early initiation of TKI appears beneficial; larger studies are required to fully understand the benefit of TKI and to design rational combination therapies for these patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Gene RearrangementTyrosine Kinase InhibitorsHumansIn Situ Hybridization, FluorescenceRetrospective StudiesTranscriptomePrecursor B-Cell Lymphoblastic Leukemia-Lymphoma

Substanzen

Tyrosine Kinase Inhibitors

Autor:innen und Institutionen

  • Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX.
  • Department of Hematopathology, University of Texas MD Anderson Cancer Center, Houston, TX.
  • Department of Stem Cell Transplantation, University of Texas MD Anderson Cancer Center, Houston, TX.
  • Department of Pathology, St Jude Children's Research Hospital, Memphis, TN.

ORCID-Profile: Jayastu Senapati, Elias Jabbour, Marina Konopleva, Nicholas J Short, Guilin Tang, Naval Daver, Tapan Kadia, Naveen Pemmaraju, Koichi Takahashi, Courtney DiNardo, Koji Sasaki, Gautam Borthakur, Beenu Thakral, Rashmi Kanagal-Shamanna, Keyur Patel, Farhad Ravandi, Kathryn Roberts, Charles Mullighan, Hagop Kantarjian, Nitin Jain

Förderung

  • NCI NIH HHS

Zitieren

APA

Senapati, J., Jabbour, E., Konopleva, M., Short, N. J., Tang, G., Daver, N., Kebriaei, P., Kadia, T., Pemmaraju, N., Takahashi, K., DiNardo, C., Sasaki, K., Borthakur, G., Thakral, B., Kanagal-Shamanna, R., Patel, K., Ravandi, F., Roberts, K., Mullighan, C., …, & Jain, N. (2023). Philadelphia-Like Genetic Rearrangements in Adults With B-Cell ALL: Refractoriness to Chemotherapy and Response to Tyrosine Kinase Inhibitor in ABL Class Rearrangements. JCO Precision Oncology. https://doi.org/10.1200/po.22.00707

Vancouver

Senapati J, Jabbour E, Konopleva M, Short NJ, Tang G, Daver N, et al. Philadelphia-Like Genetic Rearrangements in Adults With B-Cell ALL: Refractoriness to Chemotherapy and Response to Tyrosine Kinase Inhibitor in ABL Class Rearrangements. JCO Precision Oncology. 2023. doi:10.1200/po.22.00707

BibTeX
@article{Senapati2023,
  author = {Senapati, Jayastu and Jabbour, Elias and Konopleva, Marina and Short, Nicholas J and Tang, Guilin and Daver, Naval and Kebriaei, Partow and Kadia, Tapan and Pemmaraju, Naveen and Takahashi, Koichi and DiNardo, Courtney and Sasaki, Koji and Borthakur, Gautam and Thakral, Beenu and Kanagal-Shamanna, Rashmi and Patel, Keyur and Ravandi, Farhad and Roberts, Kathryn and Mullighan, Charles and Kantarjian, Hagop and Jain, Nitin},
  title = {Philadelphia-Like Genetic Rearrangements in Adults With B-Cell ALL: Refractoriness to Chemotherapy and Response to Tyrosine Kinase Inhibitor in ABL Class Rearrangements},
  journal = {JCO Precision Oncology},
  year = {2023},
  doi = {10.1200/po.22.00707}
}
Kostenlos starten →